EP1286590A4 - Analogues et mimetiques peptidiques pouvant etre utilises in vivo pour traiter des maladies associees au repli anormal proteique en depots amyloides ou pseudo-amyloides ou leur precurseur pathologique riche en beta-feuille - Google Patents

Analogues et mimetiques peptidiques pouvant etre utilises in vivo pour traiter des maladies associees au repli anormal proteique en depots amyloides ou pseudo-amyloides ou leur precurseur pathologique riche en beta-feuille

Info

Publication number
EP1286590A4
EP1286590A4 EP00976928A EP00976928A EP1286590A4 EP 1286590 A4 EP1286590 A4 EP 1286590A4 EP 00976928 A EP00976928 A EP 00976928A EP 00976928 A EP00976928 A EP 00976928A EP 1286590 A4 EP1286590 A4 EP 1286590A4
Authority
EP
European Patent Office
Prior art keywords
amyloid
deposits
precursor
beta
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00976928A
Other languages
German (de)
English (en)
Other versions
EP1286590A2 (fr
Inventor
Claudio Soto-Jara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axonyx Inc
Original Assignee
Axonyx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axonyx Inc filed Critical Axonyx Inc
Publication of EP1286590A2 publication Critical patent/EP1286590A2/fr
Publication of EP1286590A4 publication Critical patent/EP1286590A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP00976928A 1999-11-05 2000-11-04 Analogues et mimetiques peptidiques pouvant etre utilises in vivo pour traiter des maladies associees au repli anormal proteique en depots amyloides ou pseudo-amyloides ou leur precurseur pathologique riche en beta-feuille Withdrawn EP1286590A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16391199P 1999-11-05 1999-11-05
US163911P 1999-11-05
PCT/US2000/030416 WO2001034631A2 (fr) 1999-11-05 2000-11-04 ANALOGUES ET MIMETIQUES PEPTIDIQUES POUVANT ETRE UTILISES IN VIVO POUR TRAITER DES MALADIES ASSOCIEES AU REPLI ANORMAL PROTEIQUE EN DEPOTS AMYLOIDES OU PSEUDO-AMYLOIDES OU LEUR PRECURSEUR PATHOLOGIQUE RICHE EN β-FEUILLE

Publications (2)

Publication Number Publication Date
EP1286590A2 EP1286590A2 (fr) 2003-03-05
EP1286590A4 true EP1286590A4 (fr) 2005-05-11

Family

ID=22592138

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00976928A Withdrawn EP1286590A4 (fr) 1999-11-05 2000-11-04 Analogues et mimetiques peptidiques pouvant etre utilises in vivo pour traiter des maladies associees au repli anormal proteique en depots amyloides ou pseudo-amyloides ou leur precurseur pathologique riche en beta-feuille

Country Status (11)

Country Link
EP (1) EP1286590A4 (fr)
JP (1) JP2004513873A (fr)
KR (2) KR20020079731A (fr)
CN (1) CN1437442A (fr)
AU (1) AU781044B2 (fr)
BR (1) BR0015513A (fr)
CA (1) CA2389041A1 (fr)
EA (1) EA004739B1 (fr)
IL (1) IL149392A0 (fr)
MX (1) MXPA02004468A (fr)
WO (1) WO2001034631A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8003612B2 (en) 1997-10-08 2011-08-23 Proteotech Inc. Small peptides for the treatment of Alzheimer's disease and other beta-amyloid protein disorders
DE10101430B4 (de) * 2001-01-13 2008-10-02 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Lösliche cyclische Analoga zur Modulation der Amyloidogenese
AU2004203461B2 (en) * 2002-01-31 2009-09-03 Tel Aviv University Future Technology Development L.P. Peptides Antibodies Directed Thereagainst and Methods Using Same for Diagnosing and Treating Amyloid-Associated Diseases
US20040052928A1 (en) 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US20070021345A1 (en) 2003-06-30 2007-01-25 Ehud Gazit Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
DE10230141B4 (de) * 2002-07-04 2004-07-15 Priontype Gmbh Verfahren und Kit zur Anreicherung und zum Nachweis von veränderten Prion-Proteinen (PrPSc)
CA2489754A1 (fr) * 2002-07-08 2004-01-15 Applied Research Systems Ars Holding N.V. Peptides de rupture de feuillets-.beta.
EP1567546A2 (fr) * 2002-12-02 2005-08-31 Applied Research Systems ARS Holding N.V. Aza-peptides
CA2571168A1 (fr) * 2004-06-17 2006-01-26 Mannkind Corporation Variantes ssx-241-49 a caracteristiques de liaison avec mhi-i
AU2006217544B8 (en) * 2005-02-28 2012-04-05 Alphabeta Ab Compounds for reducing aggregation of amyloid beta-peptide
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Ｂｉｒドメイン結合化合物
EP1746422A1 (fr) * 2005-07-19 2007-01-24 Universita'degli Studi Di Milano Procédé d'identification d'inhibiteurs de pliage de protéine
AU2007280282B2 (en) * 2006-08-04 2012-02-02 Lonza Biologics Plc Method for predicting protein aggregation and designing aggregation inhibitors
TW201225972A (en) 2010-11-15 2012-07-01 Univ Ramot Dipeptide analogs for treating conditions associated with amyloid fibril formation
SG187271A1 (en) * 2011-07-07 2013-02-28 Agency Science Tech & Res Anti-amyloidogenic, alpha-helix breaking ultra-small peptide therapeutic
MX347354B (es) * 2011-08-17 2017-04-24 Ironwood Pharmaceuticals Inc Tratamientos para trastornos gastrointestinales.
DE102013016002A1 (de) * 2013-09-26 2015-03-26 Forschungszentrum Jülich GmbH Zyklische, Amyloid-Beta-bindende Peptide und deren Verwendung
EP3747454B9 (fr) 2013-09-26 2023-10-04 Priavoid GmbH Peptides liants amyloïdes-bêta et ces peptides pour leur utilisation pour le traitement et le diagnostic de la maladie d'alzheimer
MY179462A (en) * 2013-10-11 2020-11-06 Malaysian Palm Oil Board Protective effects of oil palm composition on alzheimer?s disease
KR101627106B1 (ko) 2014-03-26 2016-06-03 연세대학교 산학협력단 다중방향성을 갖는 폴리펩티드 및 이를 포함하는 자기조립 나노구조체
DE102015003676A1 (de) * 2015-03-20 2016-09-22 Forschungszentrum Jülich GmbH Fachbereich Patente Spezifisch A-Beta Spezies bindende Peptide für die Therapie und/oder die Diagnose der Alzheimerschen Demenz
EP3843768A4 (fr) 2018-05-15 2022-11-23 Tran, Lloyd Hung Loi Composition d'agent thérapeutique et procédé d'utilisation, pour le traitement d'un trouble cognitif léger, de la dépression et de troubles psychologiques

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854204A (en) * 1995-03-14 1998-12-29 Praecis Pharmaceuticals, Inc. Aβ peptides that modulate β-amyloid aggregation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948763A (en) * 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
JP2001500852A (ja) * 1996-08-27 2001-01-23 プレーシス ファーマスーティカルズ インコーポレイテッド Ｄ―アミノ酸を含むβ―アミロイドペプチド凝集のモジュレーター

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854204A (en) * 1995-03-14 1998-12-29 Praecis Pharmaceuticals, Inc. Aβ peptides that modulate β-amyloid aggregation

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ADESSI ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, 2003, pages 13905 - 13911 *
ALI ET AL., ACTA CHIMICA SCANDICANICA, vol. 27, 1973, pages 1509 - 1518 *
BASU ET AL, BIOPOLYMERS, vol. 31, 1991, pages 1763 - 1774, XP002056915 *
FAUCHERE J-L ET AL: "Evaluation of the stability of peptides and pseudopeptides as a tool in peptide drug design", ADVANCES IN DRUG RESEARCH 1992 UNITED KINGDOM, vol. 23, 1992, pages 127 - 159, XP009036334, ISSN: 0065-2490 *
GANTE J: "PEPTIDOMIMETICS-TAILORED ENZYME INHIBITORS", ANGEWANDTE CHEMIE. INTERNATIONAL EDITION, VERLAG CHEMIE. WEINHEIM, DE, vol. 33, no. 17, 16 September 1994 (1994-09-16), pages 1699 - 1720, XP000465275, ISSN: 0570-0833 *
PODUSLO J F ET AL: "BETA-SHEET BREAKER PEPTIDE INHIBITOR OF ALZHEIMER'S AMYLOIDOGENESIS WITH INCREASED BLOOD-BRAIN BARRIER PERMEABILITY AND RESISTANCE TO PROTEOLYTIC DEGRADATION IN PLASMA", JOURNAL OF NEUROBIOLOGY, JOHN WILEY AND SONS., NEW YORK, NY, US, vol. 39, no. 3, 5 June 1999 (1999-06-05), pages 371 - 382, XP009008758, ISSN: 0022-3034 *
ROSSI ET AL., BIOPOLYMERS, vol. 40, 1996, pages 465 - 478, XP009074244 *
SOTO C ET AL: "BETA-SHEET BREAKER PEPTIDES INHIBIT FIBRILLOGENESIS IN A RAT BRAIN MODEL OF AMYLOIDOSIS: IMPLICATIONS FOR ALZHEIMER'S THERAPY", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 4, no. 7, 1998, pages 822 - 826, XP000914747, ISSN: 1078-8956 *
SOTO C: "Alzheimer's and prion disease as disorders of protein conformation: implications for the design of novel therapeutic approaches", JOURNAL OF MOLECULAR MEDICINE, SPRINGER VERLAG, DE, vol. 77, no. 5, May 1999 (1999-05-01), pages 412 - 418, XP002203443, ISSN: 0946-2716 *
TONIOLO ET AL., PEPTIDE RESEARCH, vol. 5, 1992, pages 56 - 61 *

Also Published As

Publication number Publication date
AU1463501A (en) 2001-06-06
JP2004513873A (ja) 2004-05-13
EP1286590A2 (fr) 2003-03-05
WO2001034631A3 (fr) 2002-12-27
WO2001034631A2 (fr) 2001-05-17
BR0015513A (pt) 2004-07-06
MXPA02004468A (es) 2004-09-10
EA200200536A1 (ru) 2002-12-26
IL149392A0 (en) 2002-11-10
CN1437442A (zh) 2003-08-20
KR20060133114A (ko) 2006-12-22
KR20020079731A (ko) 2002-10-19
CA2389041A1 (fr) 2001-05-17
EA004739B1 (ru) 2004-08-26
AU781044B2 (en) 2005-05-05

Similar Documents

Publication Publication Date Title
EP1286590A4 (fr) Analogues et mimetiques peptidiques pouvant etre utilises in vivo pour traiter des maladies associees au repli anormal proteique en depots amyloides ou pseudo-amyloides ou leur precurseur pathologique riche en beta-feuille
WO2002046222A3 (fr) Compositions et procede de diagnostic de la maladie d'alzheimer
EP2045267A3 (fr) Anticorps humanisés qui reconnaissent le peptide d'amyloïde béta
WO2002074337A8 (fr) Inhibiteurs et/ou antagonistes de proteines hmgb1 destines au traitement de maladies vasculaires
MXPA03009772A (es) Metodos y composiciones para tratar lesiones orales y del esofago.
PL371770A1 (en) Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours
WO2003039454A8 (fr) Inhibiteurs de la beta-secretase et leurs procede d'utilisation
IL171956A0 (en) Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis
AU4541101A (en) Design and discovery of protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
IL148401A0 (en) Hsp70-derived peptides and uses thereof in the diagnosis and treatment of autoimmune diseases
GB0216972D0 (en) Peptides and peptide derivaties for the treatment of &-synuclein-related diseases
AU2002212471A1 (en) Peptides for use in the treatment of alzheimer's disease
DE69939075D1 (de) Pharmazeutische Zusammenstellung zur Vorbeugung und Behandlung von mit Zellkrankheiten des Augenhintergrundes zusammenhängenden Krankheiten
WO2001045715A3 (fr) Formulations d'agonistes d'adenosine a1
GB9929497D0 (en) Improved amino acid mixtures for the treatment and/or management of certain diseases
IL155237A0 (en) Combination therapy for the treatment of estrogen-sensitive disease
AU2001253886A1 (en) Methylxanthines in the diagnosis and treatment of autistic disorder
AU2002350751A8 (en) Compounds which can be used to diagnose and monitor diseases associated with the formation of amyloid protein fibrils
AU2003263036A8 (en) Span-xb gene and protein for the diagnosis and treatment of cancer
AU2003245858A8 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases
GB0008326D0 (en) Diagnosis and treatment of autism and related disorders
AU2002364757A8 (en) Peptides for the production of preparations for the diagnosis and therapy of autoimmun diseases
AU2003240746A8 (en) Diagnostic and therapeutic use of steroidogenic acute regulatory protein for neurodegenerative diseases
WO2001011039A3 (fr) Nouveaux variants de sequences du gene humain de l'adrenorecepteur $g(b)1
AU2003217432A8 (en) Angiopoietin-1 in the treatment of disease

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020531

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050330

17Q First examination report despatched

Effective date: 20050705

17Q First examination report despatched

Effective date: 20050705

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070522